Document:

Exhibit 10.13
                                                         CONFIDENTIAL TREATMENT
                                    Heritage Worldwide, Inc. has requested that
                               the marked portions of this document be accorded
                                  confidential treatment pursuant to Rule 24b-2
                                  promulgated under the Securities Exchange Act

            AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT

             This AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT
(the"Agreement" is made as of the 30th day of March 2004, by and between Poly
Implants Protheses, S.A., a French corporation ("Supplier") and III Acquisition
Corp., a Delaware corporation and/or its wholly owned subsidiaries
("Distributor").

                                    RECITALS

         WHEREAS the Supplier is the manufacturer of smooth and textured breast
implant products (the "Breast Implants") which Supplier desires to have
distributed throughout North America, including the United States of America and
Canada, and any territories of the United States of America and Canada (the
"Territory");

         WHEREAS the Distributor desires to distribute the Breast Implants,
along with any other products manufactured or sold by the Supplier
(collectively, the "Products") in the Territory on a non-exclusive basis;

         WHEREAS Supplier and Distributor have previously entered into a
Non-Exclusive Distribution Agreement dated as of October 27, 1999 (the "Original
Agreement") in which Supplier granted Distributor the non-exclusive right to
distribute the Products in the Territory; and

         WHEREAS Supplier and Distributor desire in this Agreement to amend and
restate the Original Agreement in its entirety to set forth in full the
agreements and understandings of the parties with respect to the distribution of
the Products in the Territory and certain related matters, including the filing,
prosecution and ownership of the Pre-Market Approval ("PMA") application
currently in preparation for Supplier's pre-filled saline Breast Implant
products, which the parties anticipate will be submitted to the United States
Department of Health and Human Resources, Food and Drug Administration (the
"FDA") no later than 2005.

         NOW, THEREFORE, in consideration of the premises and of the mutual
covenants set forth below, the parties hereto agree as follows:

         1. Distribution Rights. Supplier hereby grants to Distributor a
non-exclusive right and license to distribute the Products for sale throughout
the Territory during the term of this Agreement. Supplier agrees that if the
other non-exclusive distributor of the products, PIP/USA, Inc., breaches its
agreement with Supplier or PIP/USA, Inc.'s agreement is cancelled or terminated
for any reason, Supplier will not execute any other non-exclusive distribution

<PAGE>

agreement with any other party and this Agreement shall become exclusive with
respect to distribution of the Products in the Territory. Distributor has only
distribution rights under this Agreement. At no time while this Agreement is in
effect will Distributor, directly or indirectly (through other companies,
agents, subsidiaries or otherwise), manufacture equivalent breast implants that
conform with the PMA contemplated in this Agreement. At no time while this
Agreement is in effect will Supplier, directly or indirectly (through other
customers, agents, subsidiaries or otherwise), with the exception of the
non-exclusive distribution agreement already in place between Supplier and
PIP/USA, Inc.:

         (a) sell the Products in the Territory; or

         (b) sell the Products to any person or entity with reasonable basis to
believe that such person or entity, or someone acting on their behalf, will
resell the Products into the Territory; or

         (c) appoint or license any other person or entity as a distributor or
representative of the Products without specifically prohibiting such person or
entity, in writing, from selling or reselling the Products into the Territory;
or

         (d) sell any components and/or parts for the Products that may be used
in manufacturing the Products for any person or entity in the Territory other
than the Distributor.

         2. Terms and Renewal. This Agreement and the rights granted Distributor
hereunder shall be for an initial term of ten (10) years, beginning on the date
first written above. Thereafter, the Distributor shall have the option of
renewing this Agreement on the same terms and conditions for three (3)
additional five (5) year terms, provided Distributor is not in default of any
provisions of this Agreement at the date of renewal, which renewal shall be
automatic unless the Distributor notifies Supplier of Distributor's intent not
to renew at least sixty (60) days prior to the renewal date.

         3. Orders and Shipping.

         (a) Order Placement and Allocation. Distributor shall place all orders
for the Products with Supplier in writing on a weekly basis (the "Purchase
Orders"). Supplier shall use commercially reasonable efforts to ship the
Products on the Purchase Orders to Distributor within thirty (30) days of the
date of the Purchase Order. Distributor shall provide to Supplier monthly an
estimate of Products to be required for the following three months. In the event
an order (prorated from a weekly basis to a monthly basis) is in excess of 20%
above the budgeted order amount, then Supplier shall not be required to fulfill
such excess above 20% within such 30-day period but shall use commercially
reasonable efforts to ship the excess Products as soon as practicable.

<PAGE>

         (b) Title and Risk of Loss. All Products shall be shipped C.I.F. to the
Distributor at such location designated by Distributor or such other location as
Distributor may notify Supplier of from time to time. Supplier shall pay all
costs associated with shipping the Products to Distributor, including, without
limitation, freight costs, license fees and taxes. Distributor shall pay any
applicable customs duties and United States freight handling charges.

                                      -2-

<PAGE>

         (c) Incorrect or Erroneous Shipment. In the event the Products shipped
to Distributor do not conform to the Purchase Order, Supplier shall correct any
such errors at no cost to Distributor within ten (10) days written notice by
Distributor of such error.

         (d) Late Shipments. In the event that Supplier has not shipped Products
under the Purchase Order within forty five (45) days of the date of the Purchase
Order (a. "Late Shipment"), Supplier agrees to allow Distributor to take a
discount equal to ten percent (10%) per month (prorated for parts of months)
that the Product in such Purchase Order remains unshipped.

         (e) Minimum Purchases. The minimum number of Breast Implant units to be
purchased by Distributor from Supplier in each calendar year of this Agreement
following Clearance (as defined in Section 4(c) below) shall, unless otherwise
agreed by the parties in writing, be the figure set forth opposite each year of
this Agreement set forth below, with Year 1 being the year in which Clearance
occurs and with the amounts in Year 1 being prorated based on the number of days
in such year following the date of Clearance:

         [****]*

         In the event silicone filled Breast Implants shall hereafter be
approved or cleared for marketing in the United States, the amounts set forth
above for each year of this Agreement (or part thereof on a prorated basis)
shall be reduced to a number equal to [****]* of the number for such year set
forth above (or such actual lesser percentage amount as shall equal the actual
percentage of the total United States Breast Implant market captured by saline
filled Breast Implants).

         4. Pricing and Payment Terms.

         (a) Price. Distributor shall pay [****]* per saline Breast Implant
unit. In the event of unforseen market forces, including predatory pricing by
competitors and/or substantial increases in raw material costs, the parties
shall engage in good faith efforts to renegotiate the price of the saline Breast
Implants. Any agreed price increase will only be effective after a ninety (90)
day written notice by Supplier to Distributor. The price and terms for any
Products other than the saline Breast Implants shall be as mutually agreed upon

--------
* Confidential Treatment has been requested for the marked portion.

                                      -3-

<PAGE>

by the parties hereto. Subject to the terms of this Agreement, Distributor shall
pay a minimum price of [****]* per saline Breast Implant unit. If the weighted
average of the net sales price of saline Breast Implant Products sold by
Distributor exceeds [****]* per saline Breast Implant unit during any calendar
quarter (the amount of such excess, the "Excess Amount'), then Distributor shall
pay within 45 days of the end of such quarter to Supplier as additional purchase
price for each unit sold during such quarter an amount equal to [****]*. The
foregoing calculation shall be made by Distributor after the end of each
calendar quarter beginning with the first full calendar quarter commencing after
Clearance (as defined in Section 4(c) below). Example:

         [****]*

         (b) Terms for Payment. Distributor agrees to pay invoices as shipped
and billed by Supplier within Forty Five (45) days after delivery, less any
discounts for Late Shipments as described in Section 3(d) above. If Distributor
fails to make payment under this Section 4(b) within the time specified,
Supplier may during the time such payments remain unpaid cease making shipments
to Distributor under Section 3.

         (c) Additional Payment Agreements. Following the date an amount equal
to
         the Offset Amount (as calculated under Section 4(d) below) has been
accrued under this Section 4(c), Distributor agrees to pay to Supplier the
following sums to the extent the cumulative sums calculated hereunder exceed the
Offset Amount, such payments to be calculated and paid on a calendar quarterly
basis within 45 days of the end of each quarter (the first such period ending at
the end of the first complete calendar quarter following the date of Clearance
(as defined below), with Distributor preparing an annual reconciliation (to
account for product returns, replacements, discounts, etc.) and any adjustments
not implemented in prior quarters being implemented in the fourth quarter
payment. Commencing with FDA approval of the PMA and clearance (including
customs and labeling clearance) to market the pre-filled saline Breast Implant
Products in the United States (the date of such clearance, "Clearance"),
Distributor shall pay to Supplier for Product purchased and accepted for sale in
the United States an amount equal to the following percentages [****]*

         The years set forth above will commence with the first sale of Product
following Clearance and the first year will be the first consecutive 12-month
period beginning with the month in which Clearance occurs. Distributor shall
retain any amount otherwise payable under this Section 4(c) that equals the
Offset Amount.

         (d) Offset Amount. Notwithstanding anything to the contrary contained
in Section 4(c), Distributor shall not be obligated to pay to Supplier any sums
calculated under Section 4(c) above until such time that the cumulative amounts
calculated under Section 4(c) exceed [****]* (the "Offset Amount"). After such
time, Distributor shall have no obligation to Supplier with respect to the
Offset Amount and its sole obligation under Section 4(c) will be to pay the
future amounts in excess of the Offset Amount as calculated under Section 4(c).

--------
* Confidential Treatment has been requested for the marked portion.

                                      -4-

<PAGE>

         (e) Product Warranty Claims/Promissory Note. As of February 29, 2004,
Supplier had certain obligations to patients and doctors in respect of claims
related to products sold by PIP/USA, Inc., PIP/America, Inc. and Distributor
("Existing Claims"). Distributor will undertake to administer and pay up to
[****]*of such Existing Claim amounts, with Distributor consulting with Supplier
prior to paying any such Existing Claim amounts. If Distributor determines in
its sole discretion that payment of any Existing Claim amount is necessary or
advisable to (1) prosecute or maintain the PMA, (2) settle any presently
existing litigation or any related or similar case, (3) avoid any adverse
regulatory action, or (4) continue to market Products in the Territory, then
Distributor may without consent of Supplier pay any such Existing Claim amount.
If with respect to any Existing Claim amount Distributor does not make the
determination set forth in the immediately preceding sentence, then Distributor
will consult with Supplier in the administration of such Existing Claim. Unless
Supplier (i) engages counsel reasonably acceptable to Distributor to consult on
such Existing Claim administration and (ii) separately indemnifies Distributor
from and against any loss, claim or liability related to such Existing Claim in
a manner reasonably acceptable to Distributor, Distributor may pay such Existing
Claim amount. If Supplier engages counsel and provides the indemnity as set
forth in the immediately preceding sentence in respect of an Existing Claim
covered by such sentence, then Distributor will not pay the respective Existing
Claim amount without Supplier's consent, which consent will not unreasonably be
withheld. In consideration of the foregoing undertaking by Distributor, Supplier
will issue to Distributor a revolving promissory note (the "Note") in the
initial nominal principal amount of [****]*. The principal amount payable under
the Note shall be increased by any additional amounts paid by Distributor on
Supplier's, PIP/USA, Inc.'s or PIP/America, Inc.'s behalf with respect to
products sold by Supplier, PIP/USA, Inc., PIP/America, Inc. or Distributor in
the Territory that are not in respect of Existing Claims.

         (f) Limitations on Obligations in the Event of No Clearance. In the
event the FDA does not approve the PMA and grant marketing clearance to
Distributor for the pre-filled saline Breast Implant as a result of the action
or inaction of Supplier, including Supplier's failure to meet FDA GMP
requirements or provide adequate pre-clinical data and other information, then
the amount owed under Section 4(e) above shall equal [****]*, plus the principal
amount of the Note, and such amount shall be immediately due and payable. In the
event the FDA does not approve the PMA and grant marketing clearance to
Distributor for the pre-filled saline Breast Implant as a result of the action
or inaction of Distributor, but excluding Supplier's failure to provide any
necessary modules, information, assistance or access, then the amount owed under
the Note referred to in Section 4(e) above shall be immediately due and payable.

--------
* Confidential Treatment has been requested for the marked portion.

                                      -5-

<PAGE>

         (g) Right to Inspect. From time to time during the term of this
Agreement, Supplier and its representatives shall have the right to inspect and
make copies of the books and records of Distributor relating to sales of
Products for the purpose of confirming Distributor's compliance with the terms
of this Agreement. Such inspection may occur not more frequently than once in
any three consecutive month period and shall be during ordinary business hours
at Distributor's place of business upon not less than three business days
advance notice. Supplier shall bear all of the costs of such inspection unless
it is determined that Distributor has underpaid Supplier by an amount equal to
[****]*or more of the amounts paid during the period covered by the inspection,
in which case Distributor shall reimburse Supplier for all of such costs.

         5. Marketing Assistance. Supplier will provide Distributor with
marketing assistance as requested by Distributor at no cost to Distributor,
including but not limited to, provision of samples, "sizers" and up-to-date
brochures for the Products in languages appropriate to the Territory. Symposia
costs from the date hereof shall be the responsibility of the Distributor. Any
other promotional materials, promotional assistance and related issues shall be
determined by the mutual, written agreement of the parties.

         6. The Products.

         (a) Definition. As used in this Agreement, the terms "Products"
includes not only the products of the Supplier in existence as of the date
hereof or licensed to Supplier by any third party, but any and all products of
the Supplier in existence or licensed to Supplier by any third party at any time
while this Agreement is in effect, including all upgrades, changes, amendments,
improvements and modifications thereto, as well as, any parts and components
necessary for the repair and replacement thereof.

         (b) Packaging. Supplier shall adequately label, package and deliver the
Products in accordance with all applicable regulations, including applicable
regulations in the Territory, using references to and trademarks of the
Supplier, and Supplier shall bear all costs associated with packaging of the
Products except that Distributor shall bear all costs associated with printing
of labels and package inserts for the Products to be sold in the Territory.

         (c) Defective Products. Supplier shall accept the return of any
Products that Distributor's Quality Assurance and/or Regulatory departments find
unacceptable ("Rejected Products") and upon return of such Rejected Products,
shall provide Distributor with new Products at no cost.

         (d) Replacement Program. Supplier agrees to credit Distributor as
follows for payments made to and replacement product sent to surgeons (the
"Replacement Product") under a product warranty program. The Supplier agrees to

--------
* Confidential Treatment has been requested for the marked portion.

                                      -6-

<PAGE>

the following reimbursement to the Distributor for saline Breast Implants:

         [****]*

         (e) Replacement Procedure. Supplier agrees that Distributor, in its
sole discretion, may send Replacement Product and payments to surgeons to cover
re-implantation (the "Re-Implantation Fees") and, upon written notice by
Distributor describing the original product, the Replacement Product and the
Re-Implantation Fees, Supplier agrees to credit the Distributor for [****]*.

         (f) Representations, Warranties and Covenants. Supplier represents,
warrants and covenants that:

         (i) Supplier has the right, title and interest in and to the
distribution of the Products necessary to enter into and perform its obligations
to Distributor hereunder; and

         (ii) The Products operate and perform as intended; and

         (iii) Supplier has complied with all applicable laws and regulations
with respect to the Products, including, without limitation, FDA approval and
compliance; and

         (iv) Subject to Sections 7 and 8 below, during the term of this
Agreement Supplier will be solely responsible for, and have a continuing
obligation to obtain and maintain, all necessary non-Territory government and
regulatory approvals and compliance with respect to the Products; including ISO
certification, and all necessary GMP certification relating to the Territory;
and

         (v) Supplier will be responsible for funding for all of its non-PMA
application costs, including (A) Supplier's United States litigation and
settlement costs (including indemnity responsibilities), (B) United States
warranty and deflation costs and (C) other product liability claims arising from
Supplier's Breast Implants sold in the United States; and

         (vi) Supplier will immediately pay all accrued sums presently owed Paul
Andre and terminate the current contract with Paul Andre and release him from
any conflict of interest in working with Distributor through delivering to Mr.
Andre any letter reasonably requested by him; and

         (vii) Supplier will immediately pay all accrued sums presently owed
Hale & Dorr LLP and terminate its relationship with Mark A. Heller, Esq. and
Hale & Dorr LLP and release Mr. Heller and Hale & Dorr LLP from any conflict of
interest in working with Distributor through delivering to Hale & Dorr LLP any
letter reasonably requested by Hale & Dorr LLP; and

         (viii) Except as provided in Section 7 below with respect to the PMA
and future PMA-related (and other Territory regulatory approval) costs, Supplier
will remain responsible for its operations and related financial obligations,
including PIP/USA, Inc. deflation costs and indemnification costs and its other
obligations under this Agreement.

--------
* Confidential Treatment has been requested for the marked portion.

                                      -7-

<PAGE>

         (g) Indemnification- Supplier agrees to hold Distributor harmless and
indemnify, reimburse and defend Distributor, upon request, at Supplier's cost,
with mutually acceptable counsel, from any proceeding related to any claim
asserted against Distributor or its customers with respect to the Products
(including without limitation, Product liability claims) or with respect to any
previous agreements that the Supplier may have had with any other party
regarding the distribution in the Territory of the Products or which otherwise
arises out of Supplier's relationship with Distributor (including without
limitation any action arising out of the failure of Supplier to comply with any
government or regulatory requirements) and shall pay Distributor for all amounts
owed by Distributor to third persons and expenses incurred by Distributor in
connection with any such claim or suit.

         7. Regulatory Responsibilities.

         (a) From and after the date hereof, Distributor shall assume (subject
         to Section 6(f) and Section 7(b)) at Distributor's expense all
         responsibilities for the PMA application and program, and for other
         similar Territory regulatory approvals, for the pre-filled saline
         Breast Implant. Additionally, Distributor shall assume general
         management responsibilities for the explant investigation program.

         (b) Supplier agrees to conduct at its expense any additional or revised
         pre-clinical testing required for the PMA application. Supplier will be
         responsible for mechanical or other testing to be performed at
         Supplier's location and all manufacturing, process and production
         record, report and compliance preparation and maintenance. Supplier
         agrees immediately after the date hereof to provide access to
         Distributor to all records (including all past PMA-related records and
         all past and fixture manufacturing, process and production records),
         data, information, reports, clinical programs and consultants requested
         by Distributor to complete the PMA submission and subsequent FDA
         requests and to provide at its own expense all additional assistance
         requested by Distributor in connection with the PMA application, other
         regulatory applications in the Territory and future management and
         maintenance of marketing clearances in the Territory. Supplier shall
         notify Distributor immediately should Supplier become aware of any
         defect or condition which may render any of the Products in violation
         of the United States Food Drug and Cosmetic Act, FDA regulations, other
         Territory regulations or which in any way alters the specification and
         quality of the Products.

         (c) For the purpose of maximizing the likelihood of FDA GMP approval
         and clearance, Supplier agrees to allow an inspector of Distributor's
         selection to inspect Supplier's facilities, processes, operations and
         records prior to the FDA's GMP inspection of Supplier's facilities.
         Supplier further agrees promptly to implement the recommendations the
         inspector reasonably makes as necessary or appropriate for the purpose
         of obtaining FDA GMP approval and clearance. In addition, Supplier
         agrees to permit one or more representatives of Distributor or other
         experts to participate directly in cooperation with Supplier in the
         preparation of PMA application modules.

         (d) All Territory regulatory approvals (including the PMA application)
         shall be applied for, issued and registered in Distributor's name.
         Commencing immediately, the ownership of the PMA application (and
         related applications and PMA application work in process) for
         Supplier's pre-filled saline breast implant will be transferred to
         Distributor. For avoidance of doubt, Distributor will own in its own
         name the PMA and related marketing clearance once issued.

                                      -8-

<PAGE>

         8. Quality Assurance Responsibilities. Supplier agrees that, in order
         to expedite the acceptance of Products by Distributor's Quality
         Assurance and/or Regulatory departments, that Distributor will, at
         Supplier's expense, implement Quality Assurance and/or Regulatory
         programs and/or personnel into the Supplier's manufacturing facilities.
         Supplier grants Distributor the right to conduct Quality Assurance
         and/or Regulatory audits (based on Distributor's Quality Assurance
         standards, which at all times shall incorporate applicable FDA and GMP
         requirements) using Distributor's personnel, Supplier's personnel
         and/or independent consultants on a quarterly basis or more frequent
         spot basis. Supplier agrees that Supplier will cure any curable
         deficiencies within ten (10) days of written notice by Distributor of
         any such Quality Assurance and/or Regulatory audits and commence curing
         all other curable deficiencies that are curable but not reasonably
         subject of cure within 10 days. Supplier agrees to credit Distributor's
         account in the amount of [****]* that any deficiencies remain uncured
         following the ten (10) day written notice period described above.
         Similarly, following Clearance Distributor agrees to credit Supplier's
         account in the amount of [****]* that any deficiencies imposed by the
         FDA on Distributor and relating to Distributor's obligations under this
         Agreement remain uncured following the 10-day period commencing on the
         later of the date of Distributor's receipt of notice thereof from the
         FDA or the date imposed by the FDA for cure or compliance.

         9. Distributor's Representations and Warranties.

         (a) Product Warranties of Supplier. Distributor acknowledges that
         Supplier has the exclusive right to determine the product guarantees
         and warranties to be provided on each of its products, with the
         exception of the Replacement Program and other specific and implied
         warranties contained herein.

         (b) Conduct of Distributor and its Representatives. Distributor agrees
         not to make any commitments either orally or in writing with respect to
         Supplier or on Supplier's behalf unless such commitment is specifically
         authorized hereunder or Supplier specifically authorizes Distributor in
         writing make such commitment. Distributor agrees not to make any
         representations outside the agreed Territory specified in this
         Agreement or subsequently agreed to in writing by the parties hereto.
         Any leads or contacts outside the Territory generated through the
         efforts of the Distributor will be promptly forwarded to the Supplier.
         Distributor further agrees to conduct all representations in a positive
         and professional manner.

         (c) Regulatory Approvals. Subject to Sections 6(f), 7 and 8 above, from
         and after the date hereof, during the term of this Agreement
         Distributor will be solely responsible for, and have a continuing
         obligation to obtain and maintain, all necessary Territory government
         and regulatory approvals and compliance with respect to the Products,
         including prosecution of the PMA application for pre-filled saline
         implants, related clinical studies, and reporting and monitoring of
         implant recipients. Subject to Sections 6(f), 7 and 8 above,
         Distributor will pay all future costs of prosecuting the PMA
         application with the FDA.

                                      -9-

<PAGE>

         (d) Costs. Distributor will be responsible for its own non-indemnified
         litigation costs, its distributor warranty obligations and its other
         obligations under this Agreement.

         10. Operational Commitments. Distributor agrees to the following:

         (a) Rotation of Stock. Distributor shall rotate its stock of saline
         breast implants on a first-in/first-out basis of shelf life based on
         the time of receipt from Supplier. For any given size, the oldest
         saline breast implants in Distributor's stock will be dispatched first
         and the most recently received saline breast implants in any size will
         be sold last.

         (b) Controlled Conditions of Saline Breast Implant Storage. Distributor
         agrees to store the Products within a restricted access storage area
         that is secure, clean (with a documented regular cleaning program in
         force), infestation fee, temperature controlled and organized according
         to established Quality Assurance and/or Regulatory requirements.

         (c) Maintenance of Quarantine Area. Distributor shall maintain a
         clearly segregated and marked out quarantine area which is labeled as
         such and which is maintained with Distributor's Quality Assurance
         and/or Regulatory policies, including a quarantine log book.

         (d) Complaint Procedure. All complaints shall be handled by
         Distributor's established complaint procedure and the details of each
         complaint shall be forwarded by fax to Supplier on a regular basis.

         (e) Returned Products. All returned Products shall be handled by
         Distributor's established return procedure and the details of each
         return shall be documented.

         (f) Implant Tracking and Product Recalls. All Products sold by
         Distributor shall have Lot Number and Serial Number records as
         established by Distributor's Regulatory and/or Quality Assurance
         departments and Distributor shall maintain these records so that each
         and every Product, up to and including when the Product is used or
         implanted, can be tracked in accordance with the USFDA tracking
         requirements then in effect.

         (g) Medical Device Reports ("MDRs"). Any adverse effect reported by a
         patient, whether critical or chronic, which may be associated with a
         potential Product malfunction shall be immediately reported by
         Distributor according to the FDA MDR requirements then in effect.

         (h) Monitoring Implant Clinical Studies. From and after the date
         hereof, Supplier will provide non-financial cooperation to Distributor
         in the clinical studies of Supplier's saline breast implants, including
         providing non-financial cooperation to Distributor in collecting
         information and documentation from participating surgeons and
         communicating any problems with the clinical studies to Distributor.

                                      -10-

<PAGE>

         (i) Product Warranty Procedure. Distributor agrees to return to the
         Supplier (after suitable liquid sterilization), in compliance with FDA
         requirements not later than the first Tuesday of the month following
         each calendar month, all breast implants returned to Distributor in
         such month that are subject to a warranty claim. Each returned implant
         will be accompanied by (i) the related Medical Device Registration Form
         and (ii) the related Explant Data Form. If provided to Distributor by
         the physician, Distributor will also supply to Supplier on the later of
         the date set forth in the previous sentence or within three business
         days of receipt thereof (1) the related Implantation Operative Report,
         (2) the related Pre-Explantation Operative Report, and (3) in the case
         of implant deflation, related photos.

         11. Notification of Material or Process Change. Supplier shall notify
         Distributor prior to implementing any changes in the manufacture,
         assembly, labeling of the Product or the processes used to produce the
         Product (the "Change Notification"). No such change will be made by
         Supplier without first obtaining the approval of Distributor's Quality
         Assurance manager in writing. Supplier agrees to give Distributor one
         full and complete set of Supplier's Standard Operating Procedures
         ("SOPs") and Manufacturing Procedures and to provide Distributor with
         any and all revisions, corrections and/or additions to the SOPs and
         Manufacturing Procedures as implemented at Supplier's facilities.

         12. Product Documentation. Supplier agrees to forward to Distributor
         with each shipment of Product all documentation generated during the
         production of the Product including, but not limited to:

         (a) all raw material testing records;
         (b) all manufacturing records;
         (c) all sterilization reports; and
         (d) all final Product testing reports.

         Supplier agrees that any discrepancies shall be cured at Supplier's
         expense.

         13. Patents and Trademarks.

         (a) Patents. Supplier shall notify Distributor promptly of any United
States and foreign patents which may now or hereafter be pending covering any of
the Product. Supplier shall diligently prosecute any applications for United
States and foreign patents which may now or hereafter be pending covering any of
the Products and, on issuance of any such patent, prosecute each infringer
thereof. Supplier shall defend, indemnify and hold harmless Distributor from and
against any liability arising out of a claim of patent infringement made with
respect to any of the Products. Supplier agrees to repurchase from Distributor,
at a price equivalent to the full purchase price paid by Distributor, any
quantity of Products in Distributor's inventory which Products Distributor
reasonably believes it should not or cannot sell, based upon an opinion of
counsel that future sales of such Product by Distributor may result in patent
infringement, or because of a decision, whether interlocutory or final, rendered
in any patent infringement action. Supplier hereby grants to Distributor a
royalty free perpetual license to all such patents. This license will survive
during the term of this Agreement.

                                      -11-

<PAGE>

         (b) Trademarks and Trade Names. Distributor recognizes. that Supplier
is the owner of the trademarks and trade names which are used in the promotion
and sale of the Products and that Distributor has no right or interest in such
trademarks and trade names. Supplier hereby grants Distributor the royalty free
right to use Supplier's trademarks on the Products during the term of this
Agreement, it being understood that Distributor shall discontinue the use of
such trademarks upon the termination of this Agreement and disclaims any rights
in the trademarks other than the said license.

         14. Product Liability Insurance. If Supplier obtains product liability
insurance for the Products, such insurance shall contain either a vendor's
endorsement or contractual liability coverage referencing the indemnification
provisions contained herein on all Products. Upon issuance of any such product
liability insurance, Supplier shall immediately furnish to Distributor a
certificate of insurance issued by the carrier evidencing the foregoing
endorsements, coverages and limits and such insurance shall not be cancelable by
Supplier without at least fifteen (15) days prior written notice to Distributor.

         15. Default; Termination. Subject to the provisions of Section 17
below, either party shall have the right to terminate this Agreement upon
written notice if the other party hereto:

         (a) commits or suffers any act of bankruptcy or insolvency; or

         (b) shall fail to perform or fulfill, at any time and in the manner
herein provided, any obligation or condition required to be performed or
fulfilled by such party hereunder, and if such party fails to remedy any such
failure within sixty (60) days after notice thereof from the non-defaulting
party.

         The non-defaulting party shall have the right to terminate this
Agreement by giving written notice of termination to the defaulting party at any
time within ninety (90) days after the 60-day default period set forth in clause
(b) above. Termination under this Section 15 shall not be deemed an election,
but shall be in addition to other rights and remedies available to the
non-defaulting party.

         On the termination of this Agreement, for whatever reason, Supplier
shall continue to honor Distributor's orders for Products up to the effective
date of termination and, other than in connection with expiration of the term of
this Agreement, for a period of sixty (60) days thereafter and Distributor shall
pay for such Products all on the terms and conditions of this Agreement. Upon
effectiveness of termination, Distributor shall have the option of returning all
Products then in inventory to Supplier for full credit or continue to sell the
Products for a period of no more than One Hundred and Twenty (120) days after
termination, at the end of which period Distributor may then return all unsold
Products in inventory for full credit.

                                      -12-

<PAGE>

         16. Confidentiality. The parties acknowledge and agree that, pursuant
to this Agreement, valuable information of a confidential nature may be
disclosed by one or more parties to another; that such information shall be
retained by either party in confidence; and that the transmittal of such
information by any party to the another party is upon the expressed condition
that the information is to be used solely for the purpose of effectuating this
Agreement. No party shall, either during the term of this Agreement or after its
termination, use, publish or disclose or cause anyone else to use, publish or
disclose the terms and conditions hereunder, any marketing information supplied
by another party or any other information considered by either party hereto to
be confidential, proprietary or a trade secret. Notwithstanding anything in the
foregoing, the above restrictions on disclosure and use shall not apply to any
information which a party can show by written evidence was known to it at the
time of receipt from the other party or which may subsequently be obtained from
sources other than the other party who are not bound by a confidentiality
agreement with either party.

         17. Contingencies. Except with respect to obtaining or maintaining GMP
compliance and with respect to failure to maintain compliance with the Quality
Assurance programs in accordance with Section 8 above,

         (a) neither Supplier or Distributor shall be liable for its failure to
perform hereunder (except for obligations to make payments hereunder) if
performance is made impossible due to any occurrence beyond its reasonable
control, including, but not limited to, acts of God, fires, floods, wars,
sabotage, accidents, equipment failure, labor disputes or shortages, government
laws, ordinances, rules, regulations, standards or decrees, whether valid or
invalid (including but not limited to, priorities, requisitions, allocations and
price adjustment restrictions), inability to obtain raw materials, equipment or
transportation, and any other similar occurrence, and

         (b) neither Supplier nor Distributor shall be liable for its failure to
perform hereunder if Supplier or Distributor ceases or suspends the operation of
all facilities where Distributor is selling or Supplier is producing the
Products deliverable hereunder, because said facilities, the operation thereof,
and/or the product therefrom fails to comply with any governmental law,
regulation, ordinance, standard, order or decree relating to health, safety or
environmental matters.

         Notwithstanding anything to the contrary contained herein, the failure
to cure a condition set forth in this Section 17 within the times specified in
Section 15 shall be grounds for termination of this Agreement as provided in
Section 15.

         If either party reasonably believes it is impossible to take corrective
action to remedy any occurrence under clause (a) above or to achieve or maintain
compliance under clause (b) above, such party may suspend or terminate this
Agreement upon written notice to the other party in accordance with Section 15.
The party who fails to perform as a result of any occurrence described in clause
(a) or(b) above shall notify the other party of any such occurrence, setting
forth the full particulars in connection therewith, and shall promptly notify
the other party of the cessation of such occurrence. In no event shall either
party be required by this Section 17 to settle strikes, lockouts or other labor
difficulties contrary to its best interest.

                                      -13-

<PAGE>

         18. Dispute Resolution. Any dispute or controversy arising under or in
connection with this Agreement shall be settled exclusively by arbitration
conducted in the State of Delaware, before a single arbitrator in accordance
with the rules of the American Arbitration Association then in effect. Judgment
maybe entered on the arbitrator's award in any court having jurisdiction. This
Agreement and the parties' performance under it shall be construed in accordance
with the laws of the State of Delaware.

         19. Miscellaneous.

         (a) Assignment. Except as expressly provided herein, neither this
Agreement nor any rights or obligations hereunder may be assigned by either
party without the written consent of the other party; provided, however, that
the rights and obligations of Distributor or MediCor hereunder may be assigned
to any entity controlled by MediCor; provided that such entity assumes all
rights and obligations of Distributor or MediCor, as applicable, hereunder and
Distributor remains liable for all of its obligations hereunder incurred prior
to the effective date of such assignment.

         (b) Waiver. Failure of either party to exercise or enforce any right
under this Agreement upon one occasion shall not waive the right to exercise or
enforce the same on another occasion. The waiver by either party of one or more
terms, conditions or defaults of this Agreement shall not constitute a waiver of
the remaining terms and conditions or of any future defaults of this Agreement.

         (c) Governing Law. The validity, interpretation and performance of this
Agreement shall be controlled by and construed under the laws of the State of
Delaware.

         (d) Headings. The headings appearing in this Agreement are inserted
only as a matter of convenience and in no way define, limit, construe or
describe the scope or extent of such section or in any way affect such
paragraph.

         (e) Counterparts. This Agreement may be executed in one or more
counterparts, all of which taken together shall constitute a single instrument
and agreement.

         (f) Notices. Any notices under this Agreement shall be in writing
addressed to the Chief Executive Officer of such party at the address set forth
on the signature page hereof, or such other addresses as a party may notify the
other party in writing) and shall be delivered by certified mail, return receipt
requested or by an overnight delivery service of international standing.

         (g) Acknowledgment The parties, and each of them, represent and warrant
that, in entering into this Agreement; they have read this Agreement, they have
had this Agreement explained by counsel of their choice, they are aware of the
contents and legal effect of this Agreement and they are acting on the advice of
counsel of their choice.

         (h) Expenses. Each party shall bear his or its own expenses, including
attorneys' fees, incurred by it, in connection with the negotiation, execution,
delivery and performance of this Agreement.

                                      -14-

<PAGE>

         (i) Severability. In the event that any provision of this Agreement
shall be held invalid, such provision shall not affect the validity of the
remainder of this Agreement, and the remainder of this Agreement shall be
construed as if the invalid provision or provisions had not been included.

         (j) Entire Agreement. The parties acknowledge that no representation,
promise or inducement has been made other than as set forth in this Agreement,
and that they are not entering into this Agreement in reliance upon any
representation, promise or inducement not set forth herein. This Agreement
supersedes all prior negotiations, understandings and agreements (including the
Original Agreement which it amends and restates in its entirety) of any kind,
written or oral, with respect to the subject matter hereof and contains all of
the terms and provisions of agreement between the parties hereto with respect to
the subject matter hereof; provided, however, that nothing in this Agreement
shall supersede rights or obligations of the parties under the Original
Agreement with respect to events occurring prior to the date hereof, except that
Distributor's claims under the Original Agreement for reimbursement for
PMA-related clinical study costs under the Original Agreement shall be canceled
hereby in consideration of the transfer to Distributor of the PMA and
Distributor's claims under the Original Agreement in respect of product
replacement costs and legal expenses accrued through February 29, 2004 shall be
canceled hereby.

                                      -15-

<PAGE>

         IN WITNESS WHEREOF, and intending to be legally bound hereby, the
parties hereto have executed this Agreement the day and year first above
written.

         "Supplier"                               "Distributor"

         Poly Implants Protheses, S.A.            III Acquisition Corp.

         By: /s/ Jean Claude Mas                   By: /s/ Donald K. McGhan
             -------------------------------           ------------------------
         Title: President                          Title: Chairman
                ----------------------------              ---------------------

         Address:   337 Avenue de Bruxelles         Address:4560 S. Decatur Blvd
                    83514 La Seyne Sur Mer France           Suite 300
                                                            Las Vegas, NV 89103

         Phone:   +33 (04) 94-10-98-10              Phone:  +1 (702) 932-4560

         Fax:     +33 (04) 94-10-98-11              Fax:    +1 (702) 932-4561

         Signed under the condition that the Promissory Note will conform to the
         paragraph 4 (e)Exhibit 10.14

                                                          CONFIDENTIAL TREATMENT
                                     Heritage Worldwide, Inc. has requested that
                                the marked portions of this document be accorded
                                   confidential treatment pursuant to Rule 24b-2
                                   promulgated under the Securities Exchange Act

                          POLY IMPLANTS PROTHESES, S.A.

                         6.75% REVOLVING PROMISSORY NOTE

                                                               March 30, 2004

Poly Implants Protheses, S.A. (the "Company"), a French societe anonyme,
promises to pay to III Acquisition Corp., a Delaware corporation ("III") or its
assigns (collectively, the "Holder"), at the time described below, the principal
sum of [****]*. The Company also promises to pay interest on the balance of that
principal sum which is unpaid from time to time at the rate of 6.75% per annum.

Concurrently herewith, the Company and III are entering into an Amended and
Restated Non-Exclusive Distribution Agreement dated as of March 30, 2004 (the
"Agreement"). As provided in Section 4(e) of the Agreement, as of February 29,
2004, the Company had certain obligations to patients and doctors in respect of
claims related to products sold by PIP/USA, Inc. and III (which does business
under the name PIP.America) ("Existing Claims"). III has undertaken in the
Agreement to administer and pay up to [****]* of such Existing Claim amounts,
with III consulting with the Company prior to paying any such Existing Claim
amounts after the date hereof. As provided in the Agreement, if III determines
in its sole discretion that payment of any Existing Claim amount is necessary or
advisable to (1) prosecute or maintain the PMA (as defined in the Agreement),
(2) settle any presently existing litigation or any related or similar case, (3)
avoid any adverse regulatory action, or (4) continue to market Products (as
defined in the Agreement) in any geographical market in the Territory (as
defined in the Agreement), then III may without consent of the Company pay any
such Existing Claim amount. As provided in the Agreement, if with respect to any
Existing Claim amount III does not make the determination set forth in the
immediately preceding sentence, then III will consult with the Company in the
administration of such Existing Claim. As provided in the Agreement, unless the
Company (i) engages counsel reasonably acceptable to III to consult on such
Existing Claim administration and (ii) separately indemnifies III from and
against any loss, claim or liability related to such Existing Claim in a manner
reasonably acceptable to III, III may pay such Existing Claim amount. As
provided in the Agreement, if the Company engages counsel and provides the
indemnity as set forth in the immediately preceding sentence in respect of an
Existing Claim covered by such sentence, then III will not pay the respective
Existing Claim amount without the Company's consent, which consent will not
unreasonably be withheld. In consideration of the foregoing undertakings by III,
the Company has issued to III this Note in the initial nominal principal amount
of [****]*. As provided in paragraph 6 below, the principal amount payable under
this Note shall be increased by any additional amounts paid by III, on the
Company's PIP/USA, Inc.'s or III's behalf with respect to products sold by the
Company, PIP/USA, Inc. or III in the Territory that are not in respect of
Existing Claims.

1. The unpaid principal balance of the sum evidenced by this Note will be due
and payable, as follows:
         (a) Each time the III becomes obligated to make a payment (an
"Additional Payment") to the Company under Section 4(c) of an Amended and
Restated Non-Exclusive Distribution Agreement dated March 30, 2004 (the
"Distribution Agreement") between the Company and III, (i) III will not make the
Additional Payment to the Company, and (ii) the outstanding balance of the
principal sum evidenced by this Note will be reduced by an amount equal to the

--------
* Confidential Treatment has been requested for the marked portion.

<PAGE>

payment III was to have made to the Company. This paragraph will constitute an
assignment by the Company to the Holder of the right to receive all the
Additional Payments from III until the principal sum evidenced by this Note has
been paid in full. However, the reduction of the principal sum evidenced by this
Note will be effective whether or not III makes the payment to the Holder.

         (b) If the Distribution Agreement is terminated for any reason,
including, but not limited to, because the products that are the subject of the
Distribution Agreement do not receive governmental approvals that are required
to permit them to be sold in the Territory described in the Distribution
Agreement, because III or the Company ceases or suspends the operation of all
facilities where III is selling or the Company is producing the products that
are the subject of the Distribution Agreement, the entire balance of the
principal sum evidenced by this Note will be due and payable on the day the
Distribution Agreement terminates.

2. Interest will be payable on the first day of January, April, August and
October of each year (each an "Interest Payment Date"), with the first interest
payment to be made on the first Interest Payment Date after the date of this
Note, except that no interest payment will be due on April 1, 2004.

3. Each payment of principal or interest will be made to the Holder by certified
or bank cashier's check or wire transfer, at such address or to such account as
the Holder specifies to the Company in writing at least three business days
before the payment is to be made.

4. Any payment of principal or interest which is not made when it is due will
bear interest from the day it is due until it is paid at the rate which is 200
basis points higher than the interest rate in effect on the day the payment is
due, or such lower rate as is the maximum rate permitted by law.

5. The Company may at any time prepay all or any portion of the outstanding
balance of the principal sum evidenced by this Note, provided that each
prepayment must be at least $50,000, or such lesser amount as is the entire
principal sum which is outstanding immediately before the prepayment. Each
prepayment of principal will be accompanied by all accrued but unpaid interest
on the principal sum being prepaid.

6. (a) Whenever the Company notifies III, or III otherwise becomes aware, that a
claim other than an Existing Claim (an "Additional Claim") has been made against
the Company, PIP/USA or III in the United States of America for breach of
warranty or for liability relating to products distributed in the United States,
III will review the Additional Claim and recommend to the Company that the
Company either (a) pay the Additional Claim in full, (b) make a partial payment
in settlement of the Additional Claim, or (c) deny liability for the Additional
Claim. In any instance in which III recommends that the Company pay an
Additional Claim in full, or in which III recommends that the Company pay an
amount in settlement of the Additional Claim and the claimant agrees to accept
that amount in full settlement of the Additional Claim, the Company will pay the
recommended amount within 30 days after III recommends that it do so.

         (b) If the Company fails to pay an Additional Claim as recommended by
III within 30 days after III recommends that the Company make the payment, III
may, but will not be required to, pay the Additional Claim and add the sum that
III paid to the principal balance due this Note. At III's request, the Company
will acknowledge that the principal balance of this Note has been increased by
the amount of the payment made by III (and, if III so requests, issue a new Note
reflecting the increased principal balance in exchange for the existing Note).

         (c) The Company hereby indemnifies III and its parent, subsidiaries,
shareholders, directors, officers, employees and agents, against and agrees to
hold each of them harmless from, any liabilities costs or expenses any of them
may incur, because the Company fails to pay an amount that III recommends in
accordance with paragraph 6(a) within 30 days after III recommends the payment.

<PAGE>

7.  Each of the following events will constitute an Event of Default:

         (a) The Company fails to make any payment of principal on or before the
             day on which it is due; or

         (b)  The Company fails to make any payment of interest within ten days
              after the day on which is it due; or

         (c) The Company defaults in any of its obligations under this Note
other than obligations described in subparagraphs (a) and (b) and fails to cure
that default within 30 days after a written demand from the Holder that the
Company do so; or

         (d) The Company, Heritage Worldwide, Inc., a Delaware corporation
("HWWI") or a significant subsidiary of either (as that term is defined in
Securities and Exchange Commission Regulation S-X) commences a proceeding
seeking relief as a debtor under any French, U.S. or other insolvency law; or

         (e) An order is entered in a proceeding under any French, U.S. or other
insolvency law declaring the Company, HWWI or a significant subsidiary of either
to be insolvent or appointing a receiver or similar official for substantially
all the Company's, HWWI's or a significant subsidiary's properties, and that
order is not dismissed within 90 days; or

         (f) Because of events of default, holders of indebtedness of the
Company for borrowed money aggregating $100,000 accelerate the time when that
indebtedness is due and payable.

8. Upon the occurrence of an Event of Default, the Holder may, by a notice to
the Company given while the Event of Default is continuing, declare the entire
unpaid balance of the principal sum evidenced by this Note and all accrued but
unpaid interest to be due and payable, in which event that principal balance and
accrued but unpaid interest will be immediately due and payable, except that if
the Event of Default is of the type described in subparagraph (d) or (e), the
entire unpaid balance of the principal sum evidenced by this Note and all
accrued but unpaid interest will be immediately due and payable when the Event
of Default occurs, without requiring any notice or other action by the Holder.

9. No amendment of this Note, waiver of any provision of this Note, or extension
of the time by which the Company must make any payment of principal or interest
required by this Note, will be effective unless it is made in writing by the
Holder. Any waiver or extension will be effective only in the instance and for
the purpose for which it is given.

10. The remedies provided in this Note are cumulative and are not exclusive of
any other remedies provided by law. The Company will pay on demand any expenses
(including reasonable attorneys fees and expenses) incurred by the Holder in
enforcing its rights under this Note.

11. Any notice or other communication required or permitted to be given under
this Note must be in writing and will be deemed given on the day when it is
delivered in person or sent by facsimile (with proof of receipt at the number to
which it is required to be sent), or on the third business day after the day on
which it is mailed by first class mail from within the United States of America,
addressed (i) if to the Company, to the Company's principal executive offices
and to the principal facsimile number at those executive offices, Attention:
President, or at such other address or facsimile number as the Company may
specify to the Holder in writing, and (ii) if to the Holder, at the address or
facsimile number specified by the Holder to the Company in writing.

12. This Note will be binding upon the Company and its assigns, and will inure
to the benefit of the Holder and the Holder's assigns. This Note will be
governed by, and construed under, the laws of the State of Delaware in the
United States of America, without regard to principles of conflicts of laws that
might apply the laws of another jurisdiction.

<PAGE>

13. The Company agrees that any action or proceeding to collect any principal or
interest due under this Note or to enforce any other provision of this Note may
be brought in any state or federal court sitting in Wilmington, Delaware in the
United States of America, and the Company (i) submits to the jurisdiction of
each of those courts for the purpose of any such action or proceeding, (ii)
agrees not to seek to change the venue of any such action or proceeding which is
brought in any of those courts, whether because of inconvenience of the forum or
otherwise (but nothing in this Paragraph will prevent a party from removing an
action or proceeding from a state court sitting in Wilmington, Delaware to a
Federal court sitting in that county), and (iii) agrees that process in any such
action or proceeding may be served by registered mail or in any other manner
permitted by the rules of the court in which the action or proceeding is
brought. .

IN WITNESS WHEREOF, the Company is executing this Note on the date shown on the
first page.

                                          POLY IMPLANT PROTHESES, S.A.

                                         By:   /s/ Jean-Claude Mas
                                               --------------------------------
                                               Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]